{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:44:48Z","timestamp":1792683888110,"version":"4.5.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Multiple myeloma (MM) is an important hematological malignancy in older adults, with a relatively poor prognosis. We aimed to present the current global patterns of incidence and mortality from MM, and predict new cancer cases and deaths by 2045.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Estimated numbers of MM cases and deaths and age-standardized (World) incidence and mortality rates per 100\u00a0000 people were obtained from the GLOBOCAN 2022 database covering 185 countries. Based on the incidence and mortality rates for 2022 and UN population estimates up to 2045, cases and deaths were predicted up to 2045.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>Globally, 188\u00a0000 MM cases and 121\u00a0000 deaths were estimated in 2022. Eastern Asia and Northern America accounted for one-fifth of all cases each (21% and 19% respectively), followed by South-Central Asia (11%), and Western Europe (9%). The incidence rates were higher in men than in women with similar geographical patterns. While the incidence rates were highest in Northern America and Australia\/New Zealand (\u22654\/100\u00a0000 for both sexes combined), the highest mortality rates (1.8\/100\u00a0000) were found in Australia\/New Zealand, Northern Europe, and Southern Africa. In the absence of changing rates, the estimated incidence and mortality of MM will increase by 71% and 79%, respectively by 2045 relative to 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation<\/jats:title>\n                    <jats:p>Our study highlights the substantial burden and variations in MM incidence and mortality reflecting global disparities in diagnosis and treatment. Improved surveillance and better disease control is needed to mitigate the global impact of MM in the presence of population aging and growth.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jnci\/djae321","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T07:28:06Z","timestamp":1733729286000},"page":"907-914","source":"Crossref","is-referenced-by-count":99,"title":["The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045"],"prefix":"10.1093","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2993-7919","authenticated-orcid":false,"given":"Allini","family":"Mafra","sequence":"first","affiliation":[{"name":"Cancer Epidemiology and Prevention Group (EPI CAN), Department of Precision Health, Luxembourg Institute of Health, Strassen L-1445,","place":["Luxembourg"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1568-7218","authenticated-orcid":false,"given":"Mathieu","family":"Laversanne","sequence":"additional","affiliation":[{"name":"Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon 69007,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9824-3657","authenticated-orcid":false,"given":"Rafael","family":"Marcos-Gragera","sequence":"additional","affiliation":[{"name":"Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid 28029,","place":["Spain"]},{"name":"Epidemiology Unit and Girona Cancer Registry, Catalan Institute of Oncology, Directorate Plan of Oncology, Girona 17004,","place":["Spain"]},{"name":"Girona Biomedical Research Institute Dr. Josep Trueta (IDIBGI-CERCA), Girona 17190 Salt,","place":["Spain"]},{"name":"Josep Carreras Leukaemia Research Institute, Girona 17004,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8714-0023","authenticated-orcid":false,"given":"Humberto V S","family":"Chaves","sequence":"additional","affiliation":[{"name":"Department of Hematology, AC Camargo Cancer Center, S\u00e3o Paulo 01509-010,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8609-0788","authenticated-orcid":false,"given":"Charlene","family":"Mcshane","sequence":"additional","affiliation":[{"name":"Centre for Public Health, Institute of Clinical Sciences Block B, Royal Victoria Hospital, Belfast BT12 6BJ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3248-7787","authenticated-orcid":false,"given":"Freddie","family":"Bray","sequence":"additional","affiliation":[{"name":"Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon 69007,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5849-4782","authenticated-orcid":false,"given":"Ariana","family":"Znaor","sequence":"additional","affiliation":[{"name":"Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon 69007,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,10]]},"reference":[{"key":"2025050719572522000_djae321-B1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2025050719572522000_djae321-B2","volume-title":"Global Cancer Observatory: Cancer Today","author":"Ferlay","year":"2024"},{"key":"2025050719572522000_djae321-B3","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"2025050719572522000_djae321-B4","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"key":"2025050719572522000_djae321-B5","volume-title":"Agents Classified by the IARC Monographs","author":"International Agency for Research on Cancer","year":"2023"},{"key":"2025050719572522000_djae321-B6","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMsr1606602","article-title":"Body fatness and cancer\u2014viewpoint of the IARC Working Group","volume":"375","author":"Lauby-Secretan","year":"2016","journal-title":"N Engl J Med"},{"key":"2025050719572522000_djae321-B7","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1038\/s41467-018-04989-w","article-title":"Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma","volume":"9","author":"Went","year":"2018","journal-title":"Nat Commun"},{"key":"2025050719572522000_djae321-B8","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2008-12-192575","article-title":"Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance","volume":"114","author":"Vachon","year":"2009","journal-title":"Blood"},{"key":"2025050719572522000_djae321-B9","volume-title":"International Classification of Diseases, 10th Revision (ICD-10)","author":"World Health Organization","year":"1999"},{"key":"2025050719572522000_djae321-B10","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: an overview","author":"Ferlay","year":"2021","journal-title":"Intl Journal of Cancer"},{"key":"2025050719572522000_djae321-B11","author":"United Nations Statistics Division","year":"2021"},{"key":"2025050719572522000_djae321-B12","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/ijc.31937","article-title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods","volume":"144","author":"Ferlay","year":"2019","journal-title":"Int J Cancer"},{"key":"2025050719572522000_djae321-B13","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"2025050719572522000_djae321-B14","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"127","author":"Ferlay","year":"2010","journal-title":"Int J Cancer"},{"key":"2025050719572522000_djae321-B15","volume-title":"Cancer Mortality for Selected Sites in 24 Countries (1950-1957)","author":"Segi","year":"1960","edition":"2nd ed"},{"key":"2025050719572522000_djae321-B16","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-642-85849-9","volume-title":"Cancer Incidence in Five Continents: A Technical Report","author":"Doll","year":"1966"},{"key":"2025050719572522000_djae321-B17","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025050719572522000_djae321-B18","doi-asserted-by":"crossref","first-page":"e670","DOI":"10.1016\/S2352-3026(22)00165-X","article-title":"The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends","volume":"9","author":"Huang","year":"2022","journal-title":"Lancet Haematol"},{"key":"2025050719572522000_djae321-B19","doi-asserted-by":"crossref","first-page":"S247","DOI":"10.1016\/j.htct.2022.09.417","article-title":"Demographic and clinical characteristics of multiple myeloma patients in Latin America","volume":"44","author":"Hungria","year":"2022","journal-title":"Hematol Transfus Cell Ther"},{"key":"2025050719572522000_djae321-B20","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s44228-022-00017-3","article-title":"Management of multiple myeloma in the Middle East: unmet needs, challenges and perspective","volume":"4","author":"Ibrahim","year":"2022","journal-title":"Clin Hematol Int"},{"key":"2025050719572522000_djae321-B21","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s43162-021-00088-3","article-title":"Are African primary physicians suspicious enough? Challenges of multiple myeloma diagnosis in Africa","volume":"33","author":"Thokerunga","year":"2021","journal-title":"Egypt J Intern Med"},{"key":"2025050719572522000_djae321-B22","doi-asserted-by":"crossref","first-page":"e000914","DOI":"10.1136\/bmjgh-2018-000914","article-title":"How to implement new diagnostic products in low-resource settings: an end-to-end framework","volume":"3","author":"Mugambi","year":"2018","journal-title":"BMJ Glob Health"},{"key":"2025050719572522000_djae321-B23","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11356-019-04661-w","article-title":"Environmental fate of chlordecone in coastal habitats: recent studies conducted in Guadeloupe and Martinique (Lesser Antilles)","volume":"29","author":"Dromard","year":"2022","journal-title":"Environ Sci Pollut Res Int"},{"key":"2025050719572522000_djae321-B24","volume-title":"Some Halogenated Hydrocarbons. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans","author":"IARC","year":"1979"},{"key":"2025050719572522000_djae321-B25","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0140-6736(23)00180-0","article-title":"Chlordecone (Kepone) poisoning in the French Territories in the Americas","volume":"401","author":"Resiere","year":"2023","journal-title":"Lancet"},{"key":"2025050719572522000_djae321-B26","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1002\/cncr.32128","article-title":"Multiple myeloma epidemiology and patient geographic distribution in Canada: a population study","volume":"125","author":"Tsang","year":"2019","journal-title":"Cancer"},{"key":"2025050719572522000_djae321-B27","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s12094-020-02541-1","article-title":"Trends of incidence, mortality and survival of multiple myeloma in Spain. A twenty-three-year population-based study","volume":"23","author":"Chang-Chan","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"2025050719572522000_djae321-B28","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.canep.2018.01.015","article-title":"Trends of incidence, mortality, and survival of multiple myeloma in Switzerland between 1994 and 2013","volume":"53","author":"Andres","year":"2018","journal-title":"Cancer Epidemiol"},{"key":"2025050719572522000_djae321-B29","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/bjh.16674","article-title":"Incidence and survival of multiple myeloma: a population-based study of 10 524 patients diagnosed 1982-2017","volume":"191","author":"Langseth","year":"2020","journal-title":"Br J Haematol"},{"key":"2025050719572522000_djae321-B30","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(dagger)","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"key":"2025050719572522000_djae321-B31","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1200\/EDBK_175546","article-title":"Hematologic malignancies: plasma cell disorders","volume":"37","author":"Dhodapkar","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2025050719572522000_djae321-B32","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1016\/j.clml.2015.07.206","article-title":"Impact of novel therapies on multiple myeloma survival\u2013current and future outcomes","volume":"15","author":"Drawid","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025050719572522000_djae321-B33","volume-title":"SEER* Explorer Application","author":"Surveillance, Epidemiology, and End Results Program","year":"2023"},{"key":"2025050719572522000_djae321-B34","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(14)70282-7","article-title":"Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study","volume":"15","author":"Sant","year":"2014","journal-title":"Lancet Oncol"},{"key":"2025050719572522000_djae321-B35","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1200\/EDBK_238551","article-title":"Many shades of disparities in myeloma care","volume":"39","author":"Ganguly","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2025050719572522000_djae321-B36","doi-asserted-by":"crossref","first-page":"10732748221142945","DOI":"10.1177\/10732748221142945","article-title":"Cost-effectiveness analysis of CAR T-cell therapies vs antibody drug conjugates for patients with advanced multiple myeloma","volume":"30","author":"Kapinos","year":"2023","journal-title":"Cancer Control"},{"key":"2025050719572522000_djae321-B37","author":"World Health Organization"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djae321\/61022340\/djae321.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/117\/5\/907\/61022340\/djae321.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/117\/5\/907\/61022340\/djae321.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T19:57:37Z","timestamp":1746647857000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/117\/5\/907\/7920408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,10]]},"references-count":37,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,12,10]]},"published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djae321","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2024,12,10]]}}}